Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Analysis of Antipsychotic Induced Concomitant Prescribing of Antiparkinson Agents in Korea

항정신병약물 사용으로 인한 항파킨슨제 병용 현황 연구

  • Park, So-Huon (Department of Pharmacy, Inje University Ilsan Paik Hospital) ;
  • Lee, Yu-Jeung (Graduate School of Clinical Pharmacy, Sookmyung Women's University)
  • 박소현 (인제대학교 일산백병원) ;
  • 이유정 (숙명여자대학교 임상약학대학원)
  • Received : 2012.03.02
  • Accepted : 2012.05.18
  • Published : 2012.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background & Purpose: It is well known that Extrapyramidal symptoms (EPS) is induced by atypical antipsychotic agents less frequently than by typical antipsychotic agents. The purpose of this study was to evaluate differences in rates of the use of antiparkinson agent, most commonly prescribed for the management of EPS, between patients with atypical agents and those with typical agents. Methods: This cross-sectional study was conducted in a retrospective way with the Electronic Medical Record (EMR) of the 312 patients for whom the Antipsychotics were prescribed by the Psychiatry Department of the Inje University Ilsan Paik Hospital, from January of 2005 to February of 2011. They received either typical agents (N=15) or atypical agents (N=297) and those 2 groups were compared in terms of antiparkinson agent use. Also, we assessed the difference between individual atypical antipsychotic agents regarding antiparkinson agent use. Results: There was no significant difference in the rates of antiparkinson agent use between the two groups (the typical agent 13.33% vs. the atypical agent 9.76%, p = 0.6512). Meanwhile, the rates of antiparkinson agent use with aripiprazole versus quetiapine (aripirazole 25% vs. quetiapine 3.57%, p = 0.003) were significantly different, Also the rates of antiparkinson agent use with aripiprazole versus risperidone (aripiprazole 25% vs. risperidone 9.52%, p = 0.0216) had a statistical meaning. Conclusions: There was no significant difference in the rates of antiparkinson agent use between patients with atypical agents and those with typical agents. However the rate of antiparkinson agent use was significantly lower with aripiprazole compared with quetiapine or risperidone.

Keywords

References

  1. Jones PB, Barnes TR, Davies L, et al., Randomized Controlled Trial of the Effect on Quality of Life of Second vs First-Generation Antipsychotic Drugs in Schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS1). Arch Gen Psychiatry 2006; 63: 1079-1087. https://doi.org/10.1001/archpsyc.63.10.1079
  2. Casey DE. Extrapyramidal syndromes; epidemiology, pathophysiology and the diagnostic dilemma. CNS Drugs 1996; 5: 1-12.
  3. Miller CH, Mohr F, Umbricht D, et al., The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998; 59: 69-75. https://doi.org/10.4088/JCP.v59n0205
  4. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23: 637-651. https://doi.org/10.1093/schbul/23.4.637
  5. Gervin M, Browne S, Garavan J, et al., Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology. Eur Psychiatry 1999; 14: 405-409. https://doi.org/10.1016/S0924-9338(99)00228-X
  6. Leucht S, Corves C, Arbter D, et al., Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41. https://doi.org/10.1016/S0140-6736(08)61764-X
  7. Miller DD, Caroff SN, Davis SM, et al., Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008; 193: 279-288 https://doi.org/10.1192/bjp.bp.108.050088
  8. Kane JM, Fleischhacker WW, Hansen L, et al., Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 2009; 70: 627-643. https://doi.org/10.4088/JCP.08r04210
  9. Ereshefsky L, Watanabe MD, Tran-Johnson TK. Clozapine: an atypical antipsychotic agent. Clin Pharm 1989; 8: 691-709.
  10. Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psycchiatry 1989; 50: 329-338.
  11. Barnes TR, McPhillips MA. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psychopharmacol 1998; 13: S49-S57.
  12. The American Psychiatric Publishing. Textbook of Psychiatry, 3th Edition.
  13. The American Psychiatric Publishing. Textbook of Psychopharmacology, 4th Edition. Chapter34. Drug to Treat Extrapyramidal Side Effects.
  14. Xiang YT, Wang CY, Si TM, et al., Use of anticholinergic drugs in patients with schizophrenia in Asia from 2001 to 2009. Pharmacopsychiatry 2011; 44: 114-118. https://doi.org/10.1055/s-0031-1275658
  15. De Hert M, Wampers M, van WR, et al., Anticholinergic use in hospitalised schizophrenic patients in Belgium. Psychiatry Res 2007; 152: 165-173. https://doi.org/10.1016/j.psychres.2006.07.012
  16. Loga-Zec S, Loga S. Polypharmacy in the treatment of schizophrenic patients in three University Centers in the Federation of Bosnia and Herzegovina (F/BH). Psychiatr Danub 2011; 23: 60-63.
  17. Rummel-Kluge C, Komossa K, Schwarz S, et al., Secondgeneration antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-tohead comparisons. Schizophr Bull 2012; 38: 167-177. https://doi.org/10.1093/schbul/sbq042